- Healthcare 150
- Posts
- Healthcare M&A Isn’t About Price Anymore
Healthcare M&A Isn’t About Price Anymore
Today we’re unpacking what will actually determine healthcare M&A winners in this cycle
Good morning, ! Today we’re unpacking what will actually determine healthcare M&A winners in this cycle, from physician alignment to tech integration, plus GSK’s $950M cardiopulmonary bet, the FDA’s approval overhaul reshaping biotech risk math, and why Latin America’s access gap is structural, not cyclical.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
Execution Is the New Alpha in Healthcare M&A
Our 420-respondent microsurvey shows this cycle has no single dominant risk — but it does have a clear theme: execution matters more than ever.
Overall responses were tightly split: Technology & data integration (26%), Physician alignment (26%), Reimbursement & regulation (24%), and Post-close execution (23%). That balance reflects a market defined by operational complexity.
Those closest to integration show stronger conviction. Corporate Development leaders (47%) rank physician alignment as the top success factor, reinforcing that retention risk is valuation risk. Meanwhile, Healthcare M&A professionals (50%) point to technology integration as the key differentiator.
Clinicians take a pragmatic view: Cardiologists prioritize reimbursement (33%) and execution (33%), signaling that economic stability outweighs systems upgrades. (More)
HEADLINE OF THE WEEK
FDA Rewrites Drug Approval — And Biotech’s Risk Math
The FDA just made one of the most market-moving regulatory shifts in years: eliminating the requirement for two independent clinical trials and proposing a faster pathway for personalized and rare-disease therapies.
The impact is immediate. Development timelines compress. Capital burn declines. Regulatory risk narrows.
For biotech—especially in gene therapy and ultra-orphan indications—this lowers structural barriers that historically made commercialization difficult. Smaller patient populations no longer face trial designs built for mass-market drugs.
For investors, this likely means risk-premium compression, earlier strategic exits, and renewed interest in mechanism-driven, early-stage assets. Expect M&A to follow as strategics reposition pipelines under a more flexible approval regime. (More)
PRESENTED BY WHEREBY
In virtual care, every failed or frustrating visit chips away at trust. Over time, that can mean lower engagement, more escalations, and higher churn risk. It also diverts product and engineering resources into troubleshooting instead of driving adoption and retention.
Telehealth teams typically switch video providers when reliability, compliance, and UX control become non-negotiable. Delaying can create silent churn, eroded trust, and stalled growth.
Whereby is a video call API built for virtual care use cases, enabling reliable, compliant embedded video with a user friendly, customizable experience. They partner closely with platforms to support a smooth setup and migration, and teams have seen support tickets drop by up to 60% soon after launch.
Built in Europe, they are trusted by leading Telehealth platforms around the world including Jane.app, Unobravo and Tebra.
If improving your virtual care experience is a priority, integrating a healthcare-focused video call solution should be on your roadmap. Speak to the team to discuss a migration plan and start testing this quarter.
Supporting our sponsors supports our free newsletters. Please support our sponsors!
DEAL OF THE WEEK
GSK’s $950M Pulmonary Push
GSK has agreed to acquire 35Pharma for $950M in cash, adding clinical-stage asset HS235 to its cardiopulmonary pipeline. The deal follows last month’s $2.2B purchase of Rapt Therapeutics and signals a clear pivot under CEO Luke Miels toward mid-stage, science-forward bolt-ons.
HS235 has completed Phase 1 and is moving into patient studies for pulmonary arterial hypertension (PAH) and broader pulmonary hypertension. The asset targets activin receptor signaling with enhanced selectivity, which GSK believes could reduce bleeding risk while potentially improving insulin sensitivity and weight profiles. In a market with limited differentiated options and meaningful morbidity, even incremental safety or metabolic advantages could shift prescribing dynamics.
Strategically, this is about pipeline insulation. With patent expiries approaching, GSK is paying up for de-risked biology that fits its respiratory, immunology and inflammation focus.
For investors, the signal is clear. Large pharma is reallocating capital toward mid-stage assets with platform adjacency, not early science. If HS235 clears Phase 2, GSK buys optionality in a growing PH market at a sub-$1B entry price. If it fails, the loss is containable. (More)
REGIONAL FOCUS
Latin America’s Access Problem Is Structural, Not Cyclical
In Latin America, patients are not postponing care because of skepticism. They are postponing because the system is hard to navigate and harder to reach.
31% of respondents cite difficult access as the primary reason for deferring care, while 24% point to affordability. Only 9% attribute delays to distrust in health professionals.
This is a supply and financing problem, not a demand problem.
For operators, that distinction matters. The bottleneck is infrastructure, network density, and front-door coordination. Not brand perception. That creates a clearer investment case for outpatient expansion, digital triage, and embedded financing models rather than marketing spend or patient engagement overlays.
For payers and governments, the data reinforces a blunt reality. Expanding nominal coverage without solving physical access and out-of-pocket exposure will not materially shift utilization.
For investors, Latin America remains an access arbitrage story. Platforms that reduce friction at the entry point of care will capture demand that already exists but remains deferred.
The opportunity is not to convince patients to seek care. It is to make care reachable. (More)
Whereby is trusted by leading telehealth platforms including Jane.app, Unobravo, and Tebra—built to support reliable, compliant embedded video at scale.
Supporting our sponsors supports our free newsletters. Please support our sponsors!
"You’ll never do a hole lot unless you’re brave enough to try"
Dolly Parton